title: Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?
abstract: Pancreatic cancer is the 4th leading cause of cancer-related death. Complete surgical resection (CR0) is considered the only curative treatment. Most patients present with unresectable or borderline resectable disease. Many small phase i/ii trials have tried to address the role of neoadjuvant treatment using chemotherapy with or without chemoradiation in the management of locally advanced disease. However, many of them looked at the rate of CR0 resection and the feasibility of such treatment. A trend for improved overall survival has been observed in the group of patients with borderline resectable disease who completed neoadjuvant treatment. A large proportion of patients progress while on treatment, sparing them from unnecessary surgery. We searched the PubMed database (using the key words "pancreatic cancer," or "pancreatic neoplasm," or "pancreatic adenocarcinoma," and "neoadjuvant treatment," or "neoadjuvant chemotherapy," or "neoadjuvant radiation therapy," or "neoadjuvant chemo-radiation," or "adjuvant therapy" [all fields] and "clinical trial" or "study") and abstracts presented at the American Society of Clinical Oncology meetings on gastrointestinal cancers. Here, we review the most recent papers that present results on neoadjuvant therapy in pancreatic cancer. All but one report used overall survival as an endpoint. Unfortunately, there are no valid biomarkers predicting tumour progression or recurrence, and response to treatment than can help to guide therapeutic choices. Our recommendation is to consider neoadjuvant treatment in cases of borderline resectable disease. In patients with primary resectable tumours, surgery followed by adjuvant treatment and enrollment on adjuvant treatment studies would be appropriate.
authors.affiliation: Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON.
authors.forename: E V
authors.initials: EV
authors.lastname: Tsvetkova
authors.affiliation: Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON.
authors.forename: T R
authors.initials: TR
authors.lastname: Asmis
keywords: Pancreatic cancer; biomarkers; borderline resectability; chemoradiation; neoadjuvant therapy
references.citation: J Clin Oncol. 2002 May 15;20(10):2537-44
references.pmid: 12011133
references.citation: Ann Surg. 1999 Aug;230(2):131-42
references.pmid: 10450725
references.citation: Ann Surg Oncol. 2012 May;19(5):1644-62
references.pmid: 22012027
references.citation: Ann Surg. 2014 Aug;260(2):372-7
references.pmid: 24374509
references.citation: Ann Surg Oncol. 2006 Sep;13(9):1201-8
references.pmid: 16955382
references.citation: PLoS Med. 2010 Apr 20;7(4):e1000267
references.pmid: 20422030
references.citation: Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):98-104
references.pmid: 12909221
references.citation: Ann Surg. 2011 Dec;254(6):882-93
references.pmid: 22064622
references.citation: Ann Surg Oncol. 2009 Jul;16(7):1727-33
references.pmid: 19396496
references.citation: Clin Cancer Res. 2011 May 15;17(10):3316-31
references.pmid: 21444679
references.citation: J Am Coll Surg. 2008 Mar;206(3):451-7
references.pmid: 18308215
references.citation: BMC Cancer. 2012 May 29;12:199
references.pmid: 22642850
references.citation: Ann Surg. 2008 Feb;247(2):300-9
references.pmid: 18216537
references.citation: JOP. 2011 Jul 08;12(4):325-9
references.pmid: 21737888
references.citation: J Transl Med. 2012 Nov 13;10:222
references.pmid: 23146106
references.citation: Cancer. 2011 May 15;117(10):2044-9
references.pmid: 21523715
references.citation: N Engl J Med. 2011 May 12;364(19):1817-25
references.pmid: 21561347
references.citation: Br J Surg. 2011 Aug;98(8):1041-55
references.pmid: 21644238
references.citation: J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8
references.pmid: 18471707
references.citation: Oncologist. 2014 Mar;19(3):266-74
references.pmid: 24569947
references.citation: Ann Oncol. 2009 Aug;20(8):1387-96
references.pmid: 19502533
references.citation: Surgery. 2011 Sep;150(3):466-73
references.pmid: 21878232
references.citation: Ann Surg. 2013 Aug;258(2):336-46
references.pmid: 23470568
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3496-502
references.pmid: 18640930
references.citation: Surgery. 2012 Sep;152(3 Suppl 1):S103-11
references.pmid: 22766366
references.citation: J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79
references.pmid: 11307091
references.citation: J Natl Cancer Inst. 1988 Jul 20;80(10):751-5
references.pmid: 2898536
references.citation: Oncologist. 2013;18(5):543-8
references.pmid: 23657686
references.citation: Ann Surg. 2005 Feb;241(2):295-9
references.pmid: 15650640
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3487-95
references.pmid: 18640929
references.citation: J Gastrointest Surg. 2004 Nov;8(7):775-84; discussion 784
references.pmid: 15531230
references.citation: ANZ J Surg. 2015 Mar;85(3):183-6
references.pmid: 24165038
references.citation: Cancer. 2013 Jan 15;119(2):277-84
references.pmid: 22778019
references.citation: J Clin Oncol. 2008 May 20;26(15):2526-31
references.pmid: 18487569
references.citation: Ann Surg Oncol. 2014 May;21(5):1530-7
references.pmid: 24473642
references.citation: J Surg Oncol. 2013 Sep;108(4):236-41
references.pmid: 23955427